CAPECITABINE TABLETS IP 500mg — PAS CAP

Product Overview — CAPECITABINE TABLETS IP 500mg (PAS CAP)

PAS CAP (Capecitabine Tablets IP 500mg) is an oral chemotherapy medication classified as a fluoropyrimidine carbamate, acting as a prodrug of 5-fluorouracil (5-FU). This targeted design allows PAS CAP to be selectively activated within tumor tissue, helping minimize systemic toxicity while delivering effective anticancer results.

The mechanism of CAPECITABINE TABLETS IP 500mg — PAS CAP disrupts DNA synthesis and RNA processing, ultimately leading to cancer cell death.

  • Strengths Available: 150 mg & 500 mg
  • Formulation: Film-coated tablets
  • Marketed by: PASKLS Pharma
  • Manufactured at: WHO-GMP Certified Facility, Himachal Pradesh, India
CAPECITABINE TABLETS IP 500mg — PAS CAP blister pack by PASKLS Pharma

Therapeutic Indications

  • Adjuvant therapy for Stage III colon cancer (alone or in combination).
  • Perioperative treatment for locally advanced rectal cancer (with chemoradiotherapy).
  • Unresectable/metastatic colorectal cancer (alone or in combination).
  • Advanced/metastatic breast cancer when anthracycline/taxane not indicated.
  • Combination with docetaxel after progression on anthracycline regimens.
  • Unresectable/metastatic gastric, esophageal, or GEJ adenocarcinoma (in combination).
  • HER2-positive gastric or GEJ adenocarcinoma (with trastuzumab).
  • Adjuvant treatment in combination with gemcitabine.

Dosage & Administration of CAPECITABINE TABLETS IP 500mg — PAS CAP

PAS CAP (Capecitabine Tablets IP 500mg) should be administered orally twice daily (morning and evening) within 30 minutes after a meal. This ensures optimal absorption and minimizes gastrointestinal side effects.

The recommended treatment cycle for PAS CAP is 14 consecutive days on medication, followed by a 7-day rest period to allow patient recovery. The exact number of cycles depends on the cancer type, disease stage, and the oncologist’s recommendation.

Dose adjustments: In patients with renal impairment, PAS CAP dosage may need modification. For moderate impairment (creatinine clearance 30–50 mL/min), a ~25% dose reduction is usually required. PAS CAP is not recommended in severe renal impairment (creatinine clearance <30 mL/min).

Dosage and administration guidelines for CAPECITABINE TABLETS IP 500mg — PAS CAP

Safety Information & Warnings — CAPECITABINE TABLETS IP 500mg (PAS CAP)

Patients taking PAS CAP (Capecitabine 500mg) may experience risks such as renal & hepatic toxicity, hyperbilirubinemia, DPD deficiency, cardiotoxicity, severe diarrhea, dehydration, skin toxicities, myelosuppression, and potential fetal harm.

PAS CAP may interact with warfarin, allopurinol, leucovorin, phenytoin, and nephrotoxic drugs. Such interactions can alter INR, reduce therapeutic efficacy, or increase toxicity risk.

CAPECITABINE TABLETS IP 500mg (PAS CAP) are contraindicated in patients with known hypersensitivity to capecitabine, 5-fluorouracil (5-FU), or any excipients. Severe renal impairment and pregnancy are also contraindications.

Patients on PAS CAP should have renal and hepatic function monitored regularly. Dose adjustments may be required for elderly patients and those with moderate renal impairment. Avoid concurrent use with anticoagulants (e.g., warfarin) without strict medical supervision.

Storage & Packaging of CAPECITABINE TABLETS IP 500mg — PAS CAP

PAS CAP (Capecitabine Tablets IP 500mg) should be stored below 30°C, in a dry place, protected from sunlight and moisture.

The product is supplied in aluminium-aluminium blister packs for maximum protection of PAS CAP tablets.

Available in convenient pack sizes suitable for hospitals and clinics.

Shelf life: 24 months from the date of manufacture when stored correctly.

Usage Restriction: For hospital/registered medical practitioner use only – not for retail sale.

CAPECITABINE TABLETS IP 500mg — PAS CAP complies with WHO-GMP quality standards and Indian Pharmacopeia specifications.

Handling Instructions: Avoid direct contact with broken PAS CAP tablets. Wash hands thoroughly after handling.

Disposal Instructions: Dispose of unused or expired PAS CAP tablets according to local regulations. Do not flush into water systems.

Labeling: Each PAS CAP blister pack contains clear labeling including batch number, manufacturing date, expiry date, and dosage strength.

Transportation: Keep PAS CAP away from extreme temperatures and humidity during transit. Use appropriate packaging to prevent physical damage.

CAPECITABINE TABLETS IP 500mg — PAS CAP packaging blister pack